Detection of drug-resistance genes of Mycoplasma pneumoniae in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia
CHEN Dan1, ZHANG Na-Li1, ZHANG Ting2, SUN Xiao-Min1
Department of General Internal Medicine, Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital/Zhengzhou Children's Hospital, Zhengzhou 450000, China
Abstract：Objective To study the drug resistance of Mycoplasma pneumoniae (MP) in the bronchoalveolar lavage fluid (BALF) of children with refractory Mycoplasma pneumoniae pneumonia (RMPP) and the distribution of drug-resistance genes, as well as the association of alleles at 2063 locus of 23SrRNA V region central ring with resistance to antimicrobial drugs. Methods BALF specimens were collected from 245 children with RMPP who were admitted to the Children's Hospital Affiliated to Zhengzhou University from March 2016 to December 2020. A rapid cultured drug sensitivity assay was used to detect the resistance of MP isolates to nine commonly used antimicrobial drugs. The real-time PCR was used to measure MP DNA. The direct sequencing was used to detect gene mutations in MP 23SrRNA V region central ring. Results Among the 245 BALF specimens, 207 tested positive for MP DNA, with a positive rate of 84.5%. The results of drug susceptibility test showed that the children with RMPP had a resistance rate of > 70% to macrolide antimicrobial drugs, with the highest resistance rate to clarithromycin, followed by roxithromycin, clindamycin, acetylspiramycin, erythromycin, and azithromycin, and these children had a resistance rate of < 5% to quinolone antimicrobial drugs. Among the 207 MP DNA-positive specimens, 41 (19.8%) had no drug-resistance gene mutations and 166 (80.2%) had drug-resistance gene mutations, among which 154 (74.4%) had an A→G mutation at 2063 locus of 23SrRNA V region central ring, 7 (3.4%) had an A→G mutation at 2064 locus, and 5 (2.4%) had mutations in both 2063 and 2064 loci. Among the 166 specimens with point mutations of the MP 23SrRNA gene, 159 (95.8%) had point mutations at 2063 locus. The A→G point mutation at 2063 locus of 23SrRNA V region central ring had a great impact on resistance to macrolide antimicrobial drugs. There was a significant difference in the distribution of alleles at 2063 locus between the children with resistance to clarithromycin, roxithromycin, clindamycin, acetylspiramycin, erythromycin, and azithromycin (P < 0.05). Conclusions MP in the BALF of children with RMPP has a relatively high resistance rate to macrolide antimicrobial drugs. Resistance to macrolide antimicrobial drugs is closely associated with the A→G point mutation in the 23SrRNA gene, and the point mutation at 2063 locus of 23SrRNA V region central ring may affect the drug-resistance mechanism of MP.
CHEN Dan,ZHANG Na-Li,ZHANG Ting et al. Detection of drug-resistance genes of Mycoplasma pneumoniae in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia[J]. CJCP, 2021, 23(7): 707-712.
Ha SG, Oh KJ, Ko KP, et al. Therapeutic efficacy and safety of prolonged macrolide, corticosteroid, doxycycline, and levofloxacin against macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children[J]. J Korean Med Sci, 2018, 33(43):e268. DOI:10.3346/jkms.2018.33.e268. PMID:30344461. PMCID:PMC6193889.
[3]
Zhang C, Zhang Q, Du JL, et al. Correlation between the clinical severity, bacterial load, and inflammatory reaction in children with Mycoplasma pneumoniae pneumonia[J]. Curr Med Sci, 2020, 40(5):822-828. DOI:10.1007/s11596-020-2261-6. PMID:33123897. PMCID:PMC7595045.
[4]
Rivaya B, Jordana-Lluch E, Fernández-Rivas G, et al. Macrolide resistance and molecular typing of Mycoplasma pneumoniae infections during a 4 year period in Spain[J]. J Antimicrob Chemother, 2020, 75(10):2752-2759. DOI:10.1093/jac/dkaa256. PMID:32653897. PMCID:PMC7678890.
[5]
Wagner K, Imkamp F, Pires VP, et al. Evaluation of lightmix mycoplasma macrolide assay for detection of macrolide-resistant Mycoplasma pneumoniae in pneumonia patients[J]. Clin Microbiol Infect, 2019, 25(3):383.e5-383.e7. DOI:10.1016/j.cmi.2018.10.006. PMID:30391582.
[6]
Lu CY, Yen TY, Chang LY, et al. Multiple-locus variable-number tandem-repeat analysis (MLVA) of macrolide-susceptible and -resistant Mycoplasma pneumoniae in children in Taiwan[J]. J Formos Med Assoc, 2020, 119(10):1539-1545. DOI:10.1016/j.jfma.2019.12.008. PMID:31924377.
Noori Goodarzi N, Pourmand MR, Arfaatabar M, et al. First detection and characterization of macrolide-resistant Mycoplasma pneumoniae from people with community-acquired pneumonia in Iran[J]. Microb Drug Resist, 2020, 26(3):245-250. DOI:10.1089/mdr.2019.0223. PMID:31545147.
[10]
Zhang YY, Zhou YL, Li SX, et al. The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children[J]. PLoS One, 2016, 11(5):e0156465. DOI:10.1371/journal.pone.0156465. PMID:27227519.
[11]
Zhou ZB, Li XZ, Chen XJ, et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China[J]. Antimicrob Agents Chemother, 2015, 59(2):1048-1051. DOI:10.1128/AAC.04308-14. PMID:25451048. PMCID:PMC4882022.
Ma ZY, Zheng YJ, Deng JK, et al. Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China[J]. Pediatr Pulmonol, 2014, 49(7):695-700. DOI:10.1002/ppul.22851. PMID:23861188.
[14]
Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae:susceptibility and resistance to antibiotics[J]. Future Microbiol, 2011, 6(4):423-431. DOI:10.2217/fmb.11.18. PMID:21526943.
[15]
Kinnear A, McAllister TA, Zaheer R, et al. Investigation of macrolide resistance genotypes in Mycoplasma bovis isolates from Canadian feedlot cattle[J]. Pathogens, 2020, 9(8):622. DOI:10.3390/pathogens9080622. PMID:32751555. PMCID:PMC7459582.
Yuan C, Min FM, Ling YJ, et al. Clinical characteristics and antibiotic resistance of Mycoplasma pneumoniae pneumonia in hospitalized Chinese children[J]. Comb Chem High Throughput Screen, 2018, 21(10):749-754. DOI:10.2174/1386207322666190111112946. PMID:30636596.
